Gail Cawkwell - Jul 1, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Medical Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Jul 1, 2022
Transactions value $
$0
Form type
4
Date filed
7/5/2022, 05:01 PM
Previous filing
Jul 5, 2022
Next filing
Feb 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Employee Stock Option (Right to Buy) Award $0 +210K $0.00 210K Jul 1, 2022 Common Stock 210K $13.83 Direct F1
transaction ACRS Restricted Stock Units Award $0 +60K $0.00 60K Jul 1, 2022 Common Stock 60K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on July 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F3 The shares underlying these restricted stock units vest in four equal annual installments beginning on July 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.